Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients

Détails

ID Serval
serval:BIB_78A35C7DC774
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients
Périodique
British Journal of Cancer
Auteur⸱e⸱s
Azria  D., Gourgou  S., Sozzi  W. J., Zouhair  A., Mirimanoff  R. O., Kramar  A., Lemanski  C., Dubois  J. B., Romieu  G., Pelegrin  A., Ozsahin  M.
ISSN
0007-0920 (Print)
Statut éditorial
Publié
Date de publication
10/2004
Volume
91
Numéro
7
Pages
1251-60
Notes
Clinical Trial
Journal Article
Multicenter Study --- Old month value: Oct 4
Résumé
Concomitant use of adjuvant tamoxifen (TAM) and radiation therapy (RT) is not widely accepted. We aim to assess whether this treatment is associated with an increased risk of developing subcutaneous fibrosis after conservative or radical surgery in breast cancer patients. We analysed 147 women with breast cancer treated with adjuvant RT, and who were included in the KFS 00539-9-1997/SKL 00778-2-1999 prospective study aimed at evaluating the predictive value of CD4 and CD8 T-lymphocyte apoptosis for the development of radiation-induced late effects. TAM (20 mg day(-1)) with concomitant RT was prescribed in 90 hormone receptor-positive patients. There was a statistically significant difference in terms of complication-relapse-free survival (CRFS) rates at 3 years, 48% (95% CI 37.2-57.6%) vs 66% (95% CI 49.9-78.6%) and complication-free survival (CFS) rates at 2 years, 51% (95% CI 40-61%) vs 80% (95% CI 67-89%) in the TAM and no-TAM groups, respectively. In each of these groups, the CRFS rates were significantly lower for patients with low levels of CD8 radiation-induced apoptosis, 20% (95% CI 10-31.9%), 66% (95% CI 51.1-77.6%), and 79% (95% CI 55-90.9%) for CD8 </=16, 16-24, and >24%, respectively. Similar results were observed for the CFS rates. The concomitant use of TAM with RT is significantly associated with an increased incidence of grade 2 or greater subcutaneous fibrosis; therefore, caution is needed for radiosensitive patients.
Mots-clé
Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal/*adverse effects/*therapeutic use Apoptosis Breast Neoplasms/*drug therapy/*radiotherapy CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Combined Modality Therapy Disease-Free Survival Female Humans Middle Aged Prospective Studies Radiation Pneumonitis/*etiology Risk Factors Tamoxifen/*adverse effects/*therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2008 17:20
Dernière modification de la notice
20/08/2019 14:35
Données d'usage